Promising targeted therapy for tough brain cancers moves forward

NCT ID NCT05278208

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 48 times

Summary

This study is testing a drug called Lutathera in children and young adults (ages 4 to 39) whose brain tumors have come back or are growing despite treatment. The drug delivers radiation directly to tumor cells that show up on a special PET scan. The goal is to find the safest dose and see if it can slow tumor growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital Colorado

    WITHDRAWN

    Aurora, Colorado, 80045, United States

  • Children's Hospital of Philadelphia

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nationwide Children's Hospital

    RECRUITING

    Columbus, Ohio, 43235, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

anaplastic ependymoma central nervous system cancer diffuse intrinsic pontine glioma embryonal neoplasm ependymoma glioma malignant glioma medulloblastoma meningioma Neoplasms, Germ Cell and Embryonal primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.